CRBU Stock Plummets 35% Premarket on RBC Target Cut
Caribou Biosciences (CRBU) shares fell over 35% in pre-market trading after RBC Capital Markets slashed its price target by 90% following the company's decision to scale back its CAR-T cancer-drug development programs.